Codage pour aza:
- powder for suspension for injection
- Intravenous use

Pour Ven:
- Tablet 
- Oral use

# Part. 1 : Monoth√©rapie ICT01

1. Group A: monotherapy, mixed solid tumors, 19-37 patients, max 6 dose levels;
2. Group B: monotherapy, advanced hematologic cancers, 18-36 patients, max 6 dose levels;
3. Group C: combination of IV ICT01 with pembrolizumab, tumors that qualified for treatment with pembrolizumab but showed no response, progressed, or relapsed during treatment, 18-36 patients, max 6 dose levels.

# Part 2

1. Group D: monotherapy ICT01 (7 and 200 mg Q3W dose levels): patients with persistent or recurrent advanced ovarian cancer;
2. Group E: monotherapy ICT01 (7 and 200 mg Q3W dose levels): patients with metastatic castration-resistant prostate cancer (mCRPC);
3. ==Group F==: ICT01 (10 and 75 mg once every 4 weeks [Q4W] dose levels) in combination with VEN/AZA administered per the package label: patients with AML who will start VEN/AZA treatment. ==Group F is implemented only in France, Spain, and the US.==
4. Group G: ICT01 (7 and 200 mg Q3W dose levels) + pembrolizumab (200 mg Q3W): patients with checkpoint inhibitor (CPI)-refractory metastatic or unresectable melanoma;
5. Group H: ICT01 (7 and 200 mg Q3W dose levels) + pembrolizumab (200 mg Q3W): patients with locally advanced or metastatic urothelial carcinoma;
6. Group I: ICT01 (7 and 200 mg Q3W dose levels) + pembrolizumab (200 mg Q3W): metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

# IB ICT01
## SAE
![[IB SAE.pdf]]


# SmpC pembrolizumab - 11-Jan-2024
![[SmPC pembro SAE.pdf]]





# Venetoclax
![[Pasted image 20240722173330.png]]
![[Protocole ICT101.png]]![[Protocole ICT101-1.png]]

